1. Hans TS, Feskens EJ, Lean ME. Association of body composition with type 2 diabetes mellitus. Diab Med 1998 ; 15: 129–35.
2. Folsom AR, Rasmussen ML, Chambless LE. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Cure 1999; 22: 1077–83.
3. Haenni A, Lithell H. Moxonidine improves insulin sensivity in insulin-resistant hypertensives. J Hypertens 1999; 17 (Suppl. 3): S29–S35.
4. Lithell H. Insulin resistance and diabetes in the context of treatment of hypertension. Blood Press 1998; (Suppl. 3): 28–31.
5. Izzo P, Beck-Nielsen H, Laakso M. Independent influence of age on basal insulin secretion in nondiabetic humans. J Clin Endocrinol Met 1999; 84: 863–8.
6. Kambham N, Markowitz G, Valeri AM. Obesityrelated glomerulopathy. An emerging epidemic. Kidney Int 2001; 59: 1498–509.
7. Chagnac A, Weinstein T, Kortzets A. Glomerular hemodynamics in severe obesity. Am J Physiol 2000; 278: F817–F822.
8. Ziegler D, Нaxhiu MA, Kaan EC. Pharmacology of moxonidme, an I1-imidazoline receptor antagonist. J Cardiovascular Pharmacol 1996; 27 (Suppl. 3): S26–S37.
9. Rupp H, Dhalla KS, Dimilla NS. Mechanism of cardiac cell damage due to catecholamines Significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 1994; 24 (Suppl. 1): S16–S24.
10. Ernsberger P. Pharmacology of moxonidine An I1-imidazoline receptor agonist. J Cardiovasc Pharmacol 2000; 35 (Suppl. 4): S27–S41.
11. Control de la hipertensiоn arterial en España, 1996. Ministerio de Sanidad у Consumo Sociedad Española de Hipertensiоn. Taga Española para la Lucha contra la Hipertensiоn Arterial.
12. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The Sixth report of the Joint National Committee on Prevention. Detection and Treatment of High Blood Pressure (JNC VI). Arch Int Med 1997; 157: 2413–46.
13. Velliqette RA, Ernsberger P. The role of l(l)- imidazoline and alpha(2)-adrenergie receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 2003; 306: 646–57.
14. Ernsberger P, Friedman ТЕ, Koletsky RJ. The l1-imidazoline receptor: Fronr binding site to therapeutic target in cardiovascular disease. J Hypertens 1997; 15 (Suppl.): S9–S23.
15. Rupp H, Jacob R. Excess catecholamines and the metabolic syndrome: Should central imidazoline receptors be a therapeutic target? Med Hypotheses 1995; 44: 217–25.
16. Ernsberger P, Graves ME, Graff LM. I1-imadazoline receptors: Definition, characterization, distribution and transmembrane signaling. Ann NY Acad Sci 1995; 763: 22–42.
17. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 2000; 35 (Suppl. 4): S1–S7.
18. Ernsberger P, Koletsky KJ, Collins LA, Bedol D. Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drugs Ther 1996; 10 (Suppl. 1): 275–82.
19. Anderson EA, Hoffman RP, Balon TW et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246–52.
20. Мaheux P, Jeppesen J, Sheu WHH et al. Additive effects of obesity, hypertension, and type 2 diabetes on insuline resistance. Hypertension 1994; 24: 695–8.
21. Scholze J, Sharma AM. Treatment of hypertension in obesity. Herz 2001; 26: 209–21.
22. Hansson L. Therapy of hypertension and metabolic syndrome: Today's standard and tomorrow's perspectives. Blood Press 1998; (Suppl. 3): 20–2.
23. Johnston CI: Future management of high blood pressure. J Cardiovasc Pharmacol 1996; 27 (Suppl. 3): S55–S60.
24. Jacob S, Klimm HJ, Reti K et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112: 315–22.
25. Koletsky RJ, Velliqette RA, Ernsberger P. The role of l(l)-imidazoline receptors and alpha(2)-adrenergie receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann NY Acad Sci 2003; 1009: 251–61.
26. Mukaddam-Daher S, Menaouar A, El-Ayoubi R et al. Cardiac effects of moxonidine in spontaneously hypertensive obese rats. Ann NY Acad Sci 2003; 1009: 244–50.
27. Ernsberger P, Koletsky KJ, Friedman JE. Molecular pathology in the obese spontaneous hypertensive Koletsky rat: A model of syndrome X. Ann NY Acad Sci 1999; 892: 272–88.
28. Friedman JE, Ishizuka T, Liu S et al. Antihyperglycemic activity of moxonidine: Metabolic and molecular effects in obese spontaneously hyperteniive rats. Blood Press 1998; (Suppl. 3): 32–9.
29. Henriksen EJ, Jacob S, Foot DL el al. Antihypertensive agent moxonidine enhance, muscle glucose transport in insulin resistant rats. Hypertension 1997; 30: 1560–5.
30. Kaan EC, Bruckner R, Frohly P et al. Effects of agmatine, and moxonidine on flucose metabolism: An intergrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995; 5 (Suppl. 1): 19–27.
31. Strojek K, Grzeszczar W, Gorska J et al. Lowering of microalbuminuria in diabetic patients by sympathicoplegic agent. Novel approach to prevent progression of diabetic nephropathy? J Am Sac Nephrol 2001; 12: 602–5.
32. Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469–78.
33. Ritz E, Amann K, Fliser D. The sympathetic nervous system and the kidney: Its importance in renal diseases. Blood Press 1998; (Suppl. 3): 14–9.
34. Amann K, Nichols C, Tornig J et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structurein experimental renal failure. Nephrol Dial Transplant 1996; 31: 1003–11.
35. Tornig J, Amann K, Ritz E et al. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure. The effects of ramipril, nifedipme and moxonidine. J Am Soc Nephrol 1996; 7: 667–75.
36. Irzyniec T, Mall G, Greber D, Ritz E. Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am J Hypertens 1992; 5: 437–43.
37. Ernsberger P, Ishizuka T, Liu S et at. Mechanisms ot antihyperglycemic effects of moxonidine in the spontaneously hypertensive Koletsky rat (SHROR). J Pharmacol Exp Ther 1999 ; 288: 139–47.
38. Rosen P, Ohhy P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-ied rat. J Hypertens 1997; (Suppl. 15): S31–S38.
39. Wiecek A, Fliser D, Nowicki M, Rit F. Effect of moxonrdinе on unnary electrolyte excretion and renal haemodynamicsinman. Eur J Clin Pharmacol 1995; 48:203–8.

José Abellán, Mariano Leal, Fernando Hernández-Menárguez, José A. GarcÍa-Galbis, Antonio Martinez-Pastor, 
Soledad Garcia de Vinuesa, José Luño

CÍtedra de Riesgo Cardiovascular, Universidad Católica de Murcia, Hospital General Universitario Gregorio Marañón, Madrid, Spain